{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:29:13Z","timestamp":1794479353935,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,12]],"date-time":"2027-06-12T00:00:00Z","timestamp":1812758400000},"content-version":"am","delay-in-days":254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA054303"],"award-info":[{"award-number":["K01DA054303"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA035165"],"award-info":[{"award-number":["T32DA035165"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL161270-03"],"award-info":[{"award-number":["5T32HL161270-03"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amepre.2026.108381","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:16:43Z","timestamp":1777857403000},"page":"108381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-258X","authenticated-orcid":false,"given":"Kevin H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-791X","authenticated-orcid":false,"given":"Nora","family":"Satybaldiyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3182-6131","authenticated-orcid":false,"given":"Wayne","family":"Kepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-0336","authenticated-orcid":false,"given":"Eric C.","family":"Leas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.amepre.2026.108381_bib0001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.amepre.2026.108381_bib0002","series-title":"Microdosing for health, healing, and enhanced performance","author":"Fadiman","year":"2025"},{"key":"10.1016\/j.amepre.2026.108381_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.amepre.2026.108381_bib0004","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1177\/13872877251389608","article-title":"A randomized clinical trial of low-dose cannabis extract in Alzheimer\u2019s disease","volume":"108","author":"Cury R de","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.amepre.2026.108381_bib0005","doi-asserted-by":"crossref","first-page":"e1410","DOI":"10.1089\/can.2023.0084","article-title":"Rational design, synthesis, and characterization of a solid \u03949-tetrahydrocannabinol nanoformulation suitable for \u201cmicrodosing\u201d applications","volume":"9","author":"Banerjee","year":"2024","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.amepre.2026.108381_bib0006","series-title":"Can you microdose THC & marijuana?","author":"McElroy","year":"2022"},{"issue":"3","key":"10.1016\/j.amepre.2026.108381_bib0007","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/businesses1030014","article-title":"Microdosing of psychoactive substances in business practice","volume":"1","author":"Lehmert","year":"2021","journal-title":"Businesses"},{"issue":"2","key":"10.1016\/j.amepre.2026.108381_bib0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J Psychoact Drugs"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.amepre.2026.108381_bib0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neubiorev.2020.09.035","article-title":"Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review","volume":"119","author":"Ona","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.amepre.2026.108381_bib0011","article-title":"Between enhancement and risk: a critical review of psychedelic microdosing","volume":"66","author":"Totomanova","year":"2025","journal-title":"Curr Opin Psychol"},{"issue":"6","key":"10.1016\/j.amepre.2026.108381_bib0012","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2025.0044","article-title":"Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial","volume":"82","author":"Mueller","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduc J"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0014","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881120953994","article-title":"Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention","volume":"36","author":"Petranker","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.amepre.2026.108381_bib0015","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","volume":"37","author":"Tagen","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.amepre.2026.108381_bib0016","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins","volume":"38","author":"Rouaud","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"22","key":"10.1016\/j.amepre.2026.108381_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214068","article-title":"Extensive collection of psychotropic mushrooms with determination of their tryptamine alkaloids","volume":"23","author":"Gotvaldov\u00e1","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0018","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamapsychiatry.2025.3038","article-title":"Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use","volume":"83","author":"Hutchison","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.amepre.2026.108381_bib0019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.amepre.2024.05.006","article-title":"Need for a public health response to the unregulated sales of Amanita muscaria mushrooms","volume":"67","author":"Leas","year":"2024","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/02791072.2024.2424284","article-title":"Global trends in psychedelic microdosing: demographics, substance testing behavior, and patterns of use","volume":"58","author":"Syed","year":"2026","journal-title":"J Psychoact Drugs"},{"issue":"6","key":"10.1016\/j.amepre.2026.108381_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1653","article-title":"Leas EC. State cannabis and psychedelic legislation and microdosing interest in the U.S","volume":"5","author":"Yang","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"5","key":"10.1016\/j.amepre.2026.108381_bib0022","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacol (Berl)"},{"issue":"10208","key":"10.1016\/j.amepre.2026.108381_bib0023","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","article-title":"Public health implications of legalising the production and sale of cannabis for medicinal and recreational use","volume":"394","author":"Hall","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.amepre.2026.108381_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the U.S","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0026","first-page":"39","article-title":"Powerful substances in tiny amounts: an interview study of psychedelic microdosing","volume":"35","author":"Johnstad","year":"2018","journal-title":"Nordisk Alkohol Nark"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02791072.2024.2304554","article-title":"Psychedelic drug microdosing practices: a qualitative online exploration","volume":"57","author":"Miller","year":"2025","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.amepre.2026.108381_bib0028","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front Psychiatry"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01811-4","article-title":"Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers","volume":"11","author":"Rootman","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.amepre.2026.108381_bib0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.amepre.2026.108381_bib0031","series-title":"U.S. psychedelic use and microdosing in 2025: insights from a probability-based and nationally representative survey","author":"Priest","year":"2026"},{"issue":"7","key":"10.1016\/j.amepre.2026.108381_bib0032","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.amepre.2026.108381_bib0033","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics: demographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.amepre.2026.108381_bib0034","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/02791072.2024.2313684","article-title":"Psychedelic microdosing among young adults from Southern California","volume":"57","author":"Harlow","year":"2024","journal-title":"J Psychoact Drugs"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03873-0","article-title":"Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany","volume":"15","author":"Sattler","year":"2025","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.amepre.2026.108381_bib0036","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2026.108381_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2026.1720348","article-title":"Self-reported use of cannabidiol as a substitute or adjunct for approved medications","volume":"14","author":"Austin","year":"2026","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.amepre.2026.108381_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2025.108026","article-title":"Leas EC. U.S. State marijuana and Delta-8-tetrahydrocannabinol laws and Delta-8-tetrahydrocannabinol use","volume":"69","author":"Satybaldiyeva","year":"2025","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0039","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s42238-025-00359-8","article-title":"Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among U.S. adults","volume":"7","author":"Satybaldiyeva","year":"2025","journal-title":"J Cannabis Res"},{"key":"10.1016\/j.amepre.2026.108381_bib0040","unstructured":"KnowledgePanel. Ipsos. https:\/\/www.ipsos.com\/en-us\/solutions\/public-affairs\/knowledgepanel. Accessed July 1, 2025."},{"issue":"8","key":"10.1016\/j.amepre.2026.108381_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28691","article-title":"Perceptions of safety of daily cannabis vs tobacco smoking and secondhand smoke exposure, 2017\u20132021","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.amepre.2026.108381_bib0042","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s11606-022-07957-9","article-title":"Perceptions of risks of cannabis use in a national sample of U.S. adults","volume":"38","author":"Kohlwes","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.amepre.2026.108381_bib0043","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.amepre.2021.09.016","article-title":"Child access prevention laws and firearm storage: results from a national survey","volume":"62","author":"Miller","year":"2022","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.amepre.2026.108381_bib0044","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.amepre.2019.06.017","article-title":"Firearm storage practices and risk perceptions","volume":"57","author":"Mauri","year":"2019","journal-title":"Am J Prev Med"},{"issue":"5","key":"10.1016\/j.amepre.2026.108381_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10918","article-title":"Consumer views on using digital data for COVID-19 control in the United States","volume":"4","author":"Grande","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.amepre.2026.108381_bib0046","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/02698811241278769","article-title":"Less is more? A review of psilocybin microdosing","volume":"38","author":"Savides","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.amepre.2026.108381_bib0047","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.amepre.2026.108381_bib0048","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/02698811211050556","article-title":"Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study","volume":"36","author":"Marschall","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.amepre.2026.108381_bib0049","unstructured":"BRFSS questionnaires. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/brfss\/questionnaires\/index.htm. Accessed February 21, 2026."},{"key":"10.1016\/j.amepre.2026.108381_bib0050","unstructured":"F.N. Mawani and H. Gilmour, Validation of self-rated mental health, Health Rep, 21 (3), 2010, 61\u201375. https:\/\/pubmed.ncbi.nlm.nih.gov\/20973435\/. Accessed March 3, 2026."},{"issue":"10","key":"10.1016\/j.amepre.2026.108381_bib0051","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s11136-014-0726-4","article-title":"Assessing the validity of single-item life satisfaction measures: results from three large samples","volume":"23","author":"Cheung","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.amepre.2026.108381_bib0052","series-title":"Analysis of complex survey samples","author":"Lumley","year":"2025"},{"key":"10.1016\/j.amepre.2026.108381_bib0053","doi-asserted-by":"crossref","DOI":"10.2196\/36667","article-title":"Using social media data to investigate public perceptions of cannabis as a medicine: narrative review","volume":"25","author":"Khademi","year":"2023","journal-title":"J Med Internet Res"},{"issue":"9","key":"10.1016\/j.amepre.2026.108381_bib0054","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035148","article-title":"Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review","volume":"10","author":"Scheim","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.amepre.2026.108381_bib0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/02791072.2024.2376755","article-title":"Magic of the mushrooms: effects of psilocybin decriminalization","volume":"57","author":"Bhave","year":"2025","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.amepre.2026.108381_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2024.116702","article-title":"Exploring the discourses around microdosing psychedelics within the r\/microdosing online community","volume":"347","author":"Pop","year":"2024","journal-title":"Soc Sci Med"},{"issue":"2","key":"10.1016\/j.amepre.2026.108381_bib0057","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02791072.2019.1683260","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"52","author":"Lea","year":"2020","journal-title":"J Psychoact Drugs"},{"issue":"12","key":"10.1016\/j.amepre.2026.108381_bib0058","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00213-020-05703-9","article-title":"Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs","volume":"237","author":"Kangaslampi","year":"2020","journal-title":"Psychopharmacol (Berl)"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379726001248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379726001248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:43:25Z","timestamp":1794476605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379726001248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0749379726001248"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2026.108381","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2026.108381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108381"}}